Eye drops to reduce dependency on reading glasses to hit Indian market soon

A pharmaceutical company basedin the Indian city of Mumbai said on Tuesday (Sep3) that it receivedapproval from the Drug Controller General of India (DCGI) to market eye drops for the treatment of presbyopia.

Entod Pharmaceuticals saidit received final approval for PresVu eye drops and plans to introduce them in the domestic market in the first week of October.

Add WION as a Preferred Source

A report by the news agency PTI said that the DCGI approval follows an earlier recommendation by the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO).

PresVu will reduce dependency on reading glasses

PresVu is the first eye drop in India that has been specifically developed to reduce dependency on reading glasses for peopleaffected by presbyopia.

According to Mayo Clinic, presbyopia is the gradual loss of your eye's abilityto focus on nearby objects. The conditionusually becomes noticeable in your early to mid-40s and continues to worsen until around age 65.

Mayo Clinic says that presbyopia can be corrected with eyeglasses, contact lenses or even surgery.

Citing industry stands, the PTI report on Tuesday said that1.09-1.8 billion individuals globally are estimated to be affected by presbyopia.

'PresVu is more than just a product'

Speaking to PTI,Entod Pharmaceuticals' Chief Executive Officer (CEO)Nikkhil K Masurkar said that the DCGI approval was a major step forward in the company's mission to transform eye care in India.

"PresVu is more than just a product; it's a solution that stands to improve the lives of millions by offering them greater visual independence," Masurkar added.

Asked about the company's future plans, Masurkar said the focus would be to cater to demand in domestic and emerging markets like Africa and South East Asia.

He also pointed out that the company aimed to innovate products in India and then out-licence them in the US market.

(With inputs from agencies)